Low Levels of Exhaled Surfactant Protein A Associated with BOS after Lung Transplantation

Transplantation Direct

Volumn 2, Issue 9, 2016, Pages E103-

  Ericson, Petrea A ^a   Mirgorodskaya, Ekaterina ^b   Hammar, Oscar S ^b   Viklund, Emilia A ^b   Almstrand, Ann Charlotte R ^b   Larsson, Per J W ^b   Riise, Gerdt C ^a   Olin, Anna Carin ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85019648717     PISSN: None     EISSN: 23738731     Source Type: Journal    
DOI: 10.1097/TXD.0000000000000615     Document Type: Article

References (24)

1. Yusen RD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: thirty-second official adult lung and heart-lung transplantation report—2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant. 2015;34: 1264–1277.
2. Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med. 2002;166:440–444.
3. Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant. 2007;26:1229–1242.
4. Verleden GM, Raghu G, Meyer KC, et al. A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant. 2014;33: 127–133.
5. Palmer SM, Burch LH, Trindade AJ, et al. Innate immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med. 2005;171:780–785.
6. Ross DJ, Cole AM, Yoshioka D, et al. Increased bronchoalveolar lavage human beta-defensin type 2 in bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2004;78:1222–1224.
7. Madsen J, Tornoe I, Nielsen O, et al. Expression and localization of lung surfactant protein A in human tissues. Am J Respir Cell Mol Biol. 2003; 29:591–597.
8. Veldhuizen R, Nag K, Orgeig S, et al. The role of lipids in pulmonary surfactant. Biochim Biophys Acta. 1998;1408:90–108.
9. Wright JR, Borron P, Brinker KG, et al. Surfactant Protein A: regulation of innate and adaptive immune responses in lung inflammation. Am J Respir Cell Mol Biol. 2001;24:513–517.
10. McCormack FX, Whitsett JA. The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. J Clin Invest. 2002;109:707–712.
11. Meloni F, Salvini R, Bardoni AM, et al. Bronchoalveolar lavage fluid proteome in bronchiolitis obliterans syndrome: possible role for surfactant protein A in disease onset. J Heart Lung Transplant. 2007;26:1135–1143.
12. Almstrand AC, Ljungström E, Lausmaa J, et al. Airway monitoring by collection and mass spectrometric analysis of exhaled particles. Anal Chem. 2009;81:662–668.
13. Bredberg A, Gobom J, Almstrand AC, et al. Exhaled endogenous particles contain lung proteins. Clin Chem. 2012;58:431–440.
14. Larsson P, Mirgorodskaya E, Samuelsson L, et al. Surfactant protein A and albumin in particles in exhaled air. Respir Med. 2012;106:197–204.
15. Larsson P, Larstad M, Bake B, et al. Exhaled particles as markers of small airway inflammation in subjects with asthma. [published online ahead of print December 9, 2016]. Clin Physiol Funct Imaging. 2015. doi: 10.1111/cpf.12323.
16. Lärstad M, Almstrand AC, Larsson P, et al. Surfactant protein A in exhaled endogenous particles is decreased in chronic obstructive pulmonary disease (COPD) patients: a pilot study. PLoS One. 2015;10:e0144463.
17. Reichenspurner H, Girgis RE, Robbins RC, et al. Stanford experience with obliterative bronchiolitis after lung and heart-lung transplantation. Ann Thorac Surg. 1996;62:1467–1472; discussion 1472–1463.
18. Riise GC, Andersson BA, Kjellström C, et al. Persistent high BAL fluid granulocyte activation marker levels as early indicators of bronchiolitis obliterans after lung transplant. Eur Respir J. 1999;14:1123–1130.
19. Almstrand AC, Bake B, Ljungstrom E, et al. Effect of airway opening on production of exhaled particles. J Appl Physiol (1985). 2010;108: 584–588.
20. Kosanke Ba. http://www.mayo.edu/research/documents/vmatchsas-0514-14/doc-20094471. Published 2004. Accessed 2016.
21. Wallinder A, Ricksten SE, Silverborn M, et al. Early results in transplantation of initially rejected donor lungs after ex vivo lung perfusion: a case-control study. Eur J Cardiothorac Surg. 2014;45:40–44; discussion 44–45.
22. Riise GC, Mårtensson G, Houltz B, et al. Prediction of BOS by the single-breath nitrogen test in double lung transplant recipients. BMC Res Notes. 2011;4:515.
23. Vos R, Verleden SE, Ruttens D, et al. Azithromycin and the treatment of lymphocytic airway inflammation after lung transplantation. Am J Transplant. 2014;14:2736–2748.
24. Almstrand AC, Josefson M, Bredberg A, et al. TOF-SIMS analysis of exhaled particles from patients with asthma and healthy controls. Eur Respir J. 2012;39:59–66.